Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison’s disease

Stephanie Burger-Stritt, Linda Bachmann, Max Kurlbaum and Stefanie Hahner
Endocrinology and Diabetes Unit, Department of Medicine I, University Hospital Wuerzburg, Wuerzburg, Germany
Correspondence should be addressed to S Hahner: Hahner_S@ukw.de

Abstract

Objective: Patients with adrenal insufficiency (AI) need to adapt their glucocorticoid replacement under stressful conditions to prevent adrenal crisis (AC). Prednisone (PN) suppositories are used for emergency treatment. Pharmacokinetics of 100 mg PN suppositories after vaginal or rectal administration was evaluated.
Design: Single-center, open-label, sequence-randomized, cross-over, bioequivalence study.
Methods: Twelve females with primary AI were included. Comparison of pharmacokinetics after vaginal and rectal administration of 100 mg PN suppositories. Main outcome measures: bioequivalence ($C_{\text{max}}$: maximum plasma concentration of prednisolone; $AUC_{0-360}$: area under the plasma concentration curve of prednisolone from administration to 360 min), adrenocorticotropin (ACTH) levels, safety and tolerability. Comparison of ACTH-suppressive effect with subcutaneous and intramuscular administration of 100 mg hydrocortisone.
Results: Vaginal administration of PN suppositories was not bioequivalent to rectal administration: $C_{\text{max}}$ and $AUC_{0-360}$ were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), $P < 0.001$; 4390 ng/mL min (116%) vs 40,302 ng/mL min (26%), $P < 0.001$; (mean (coefficient of variation), respectively). A suppression of ACTH by >50% of baseline values was observed 149 min (32%) after rectal PN administration; after vaginal PN administration, the maximum decrease within 360 min was only 44%. Adverse events were more frequent after vaginal administration and mainly attributable to the glucocorticoid deficit due to inadequate vaginal absorption. The ACTH-suppressive effect was more pronounced after parenteral hydrocortisone compared to rectal or vaginal PN.
Conclusion: Vaginal administration of PN suppositories in the available form is not useful for prevention of AC. Pharmacokinetics after rectal use of PN show inferiority compared to available data on parenteral glucocorticoids. In adrenal emergencies, hydrocortisone injection should be the first choice.

Introduction

Despite of established replacement therapy, an increased mortality of patients with adrenal insufficiency (AI) has been observed (1, 2, 3, 4). AI represented the second most frequent cause of death in a Norwegian cohort of patients with primary AI (3). The relative risk of death from infectious disease compared to the background population was 6.6 in a Swedish analysis (1). Patients with chronic AI are at risk of adrenal crisis (AC) which...
contributes to the increased mortality (5, 6, 7, 8, 9, 10, 11). An increase in cortisol secretion is an important adaptive mechanism to deal with stressful events. An AC, therefore, usually occurs under conditions of relative cortisol deficiency due to inadequate replacement at times of increased requirement. To avoid AC, patients are educated in adaptation of their glucocorticoid (GC) dose under stressful conditions (12, 13, 14). AC requires immediate initiation of parenteral administration of GCs (13, 14). As many health professionals are not familiar with this rare disease, intravenous GC replacement may be delayed (15, 16, 17). To enable patients to deal with emergency situations more independently, patients and relatives are educated in intramuscular (i.m.) hydrocortisone (HC) self-injection (18). Furthermore, off-label use of subcutaneous (s.c.) administration of HC appears to be a safe and efficient alternative (19). However, an easy to handle GC emergency set, for example, a ‘ready-to-use’ GC pen, is not available. Prednisone (PN) suppositories have been recommended by recent guidelines (14). However, the guidelines indicate that the level of evidence is low, as the rectal administration of PN (REC-PN), which is approved for the treatment of acute laryngotracheitis, croup and spastic bronchitis in children, has not been investigated in patients with AI to date. Rectal absorption in case of gastroenteritis and diarrhea is uncertain. Off-label vaginal administration of PN suppositories (VAG-PN) may be an alternative administration form. In an anonymous survey of 18 females with AI immediately following training in self-injection of GCs, 28% (n=5) preferred vaginal administration of a suppository over GC injection (own observations).

As patients with AI still die from AC, both improvement and simplification of emergency management has been postulated (10, 13, 20, 21, 22, 23, 24). We, therefore, aimed to systematically investigate the pharmacokinetic profile of PN after rectal and vaginal administration in patients with primary AI. In a sub-analysis, we compared the kinetics of ACTH plasma levels with data from a previous trial investigating HC after s.c. and i.m. administration.

Subjects and methods

Study design

The trial was conducted as a single-center, open-label, sequence-randomized, cross-over, bioequivalence study. Prednisolone levels after VAG-PN were compared to levels after REC-PN in the same patients over a period of 6h. Secondary endpoints were the safety of VAG-PN and the response of ACTH levels to GC administration as an indirect measure of biological GC activity. Patient acceptance of the different modes of PN administration was assessed by a questionnaire. The study was approved by the Ethics Committee of the University of Wuerzburg (permit no. 185/16). In addition, approval was obtained by the federal institute for drugs and medical devices (EUDRACT-No.: 2016-000332-18). The study was registered at clinicaltrials.gov (clinicaltrials.gov identifier: NCT02689960) and complies with the Declaration of Helsinki. Written informed consent was obtained from all patients before study participation. In case of discontinuation after only one study visit, the data obtained from the first study visit was still included in the analysis.

Patients

Twelve patients with primary AI registered at the outpatient department of the University Hospital Wuerzburg agreed to participate. Key inclusion criteria were female sex, chronic primary AI due to autoimmune adrenalitis, age ≥18 years, ability to comply with the protocol procedures, stable replacement therapy, no anticipated change in medication during study period, negative pregnancy test and contraception (other than hormonal contraception) in premenopausal females. Postmenopausal status was defined as >12 months lasting amenorrhea in females aged above 50 years. Key exclusion criteria were diabetes mellitus, infectious disease with fever at the time of investigation, chronic infectious disease, known intolerance to the study drug (PN) or constituents (hydrogenated fat), hormonal contraception or hormone replacement therapy with estrogens, pregnancy or breast feeding, renal failure (creatinine >2.5 ULN (upper limit of normal)), liver failure, liver cirrhosis, hepatitis, elevated transaminases (ALAT or ASAT >3 ULN), disposition to vaginal mycosis (requiring treatment in the last 6 months or need of >2 antifungal therapies/year), recurrent urinary tract infections (need of antibiotic treatment more than twice/year), duodenal or gastric ulcer, increased propensity for thrombosis, active psychiatric disease, increased intraocular pressure, heart failure (NYHA>II), untreated hypothyroidism, vaccination with an attenuated vaccine <8 weeks prior study participation, insufficiently controlled arterial hypertension (documented elevation of systolic blood pressure >140mmHg and diastolic blood pressure >90mmHg in repeated ambulatory measurements), acute enteropathy and entero-anastomosis. In premenopausal women, study visit was postponed in case of menstruation.

https://doi.org/10.1530/EC-19-0024

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Published by Bioscientifica Ltd

© 2019 The authors
Medical product

The investigational medical product (Rectodelt (Trommsdorff)) is officially registered in the European Union (approval number: 6329964.00.00). In this trial the investigational medical product was used without modification of the registered composition.

Pharmacokinetics studies

The patients were investigated in the morning. While the usual morning dose of HC was postponed and ingested after all study procedures, all further long-term medication (including fludrocortisone and levothyroxine) was ingested as usual by the patients. Six patients initially received the PN suppository vaginally and six patients rectally. The minimum time interval between study visits was 7 days. The median interval between VAG-PN and REC-PN was 8 days (7–21). The vaginal and rectal administrations were performed by the patients under supervision of an investigator to ensure correct administration. At every study visit, blood samples for the determination of serum prednisolone and plasma ACTH were collected at the following time-points: −10, 0, 10, 45, 75, 120, 180, 240, 300, 360 min and further processed within maximum 30 min after collection. A study flow chart is shown in Fig. 1.

Questionnaire and safety assessment

Patients received a diary to document any local or systemic adverse event during the following 7 days after intervention. In addition, patients were contacted by phone after VAG-PN (Fig. 1). At the end of the second study visit, patients received a questionnaire to collect general information on their adrenal disease and a personal rating of the different administration modes.

Hormone measurements

Since PN is converted to the biologically active metabolite prednisolone by hepatic 11beta-hydroxysteroid dehydrogenase type 1 (25), prednisolone levels were measured in serum. For the determination of serum prednisolone ultra-performance liquid chromatography (UPLC (Acquity) with PDA (UV)-detector; MVZ Dr. Eberhard & Partner, Dortmund, Germany) was used. Intra- and inter-assay variations given by MVZ Dr. Eberhard & Partner, Dortmund, Germany were <15%. Intra-assay coefficients of variation (CVs) during measurements were as follows (n=20): 1.63, 2.05 and 2.96%. Inter-assay CVs were as follows: 6.8, 6.3 and 5.3%. Samples with values below 7 ng/mL (=lower limit of quantitation) were rated as 0 ng/mL for calculations. ACTH levels were determined from EDTA plasma with a solid-phase, two site sequential automated chemiluminescent immunometric assay (IMMULITE 2000 ACTH (PIL2KAC-18, 2018-03-15), Siemens Healthcare Diagnostics). Statistics for intra-assay precision given for the ACTH assay from Siemens Health Care Diagnostics IMMULITE 2000 ACTH ranged from 6.7 to 9.5% (mean values). Inter-assay precision ranged from 6.1 to 10%. Measurements from our study had been performed in a certified clinical routine laboratory regularly participating in ring trials. An assay from the same batch was used for all measurements.

Pharmacokinetic analysis

Pharmacokinetic data for assessment of bioequivalence: Cmax (maximum plasma concentration of prednisolone) and AUC0–360 (area under the plasma concentration curve of prednisolone from administration to last observed concentration at time). Further pharmacokinetic data: Cavg (average plasma concentration of prednisolone), tmax (time interval between administration and maximum plasma concentration of prednisolone), MRT (mean residence time of prednisolone) and t50 (serum concentration half-life of prednisolone). Cmax and tmax were obtained directly from the observed values. Cavg was calculated as mean of all values between 10 and 360 min. AUC0–360 was assessed by the trapezoidal rule. MRT was calculated as the area under the moment curve divided by the AUC0–360. Elimination half-life was calculated using the formula: t50=ln (2)/ke. The elimination rate constant was calculated as follows: ke=(ln (C1)−ln (C2))/Δt. The biological efficacy was evaluated by the decrease of ACTH levels. Kinetic data: Cbaseline (baseline ACTH level, mean of values at −10 min and 0 min), Cmin (minimal ACTH concentration after administration of PN/HC), ΔCbaseline-min (difference between baseline and minimal ACTH level after administration of PN/HC), t50 (time to a 50% decrease of the baseline ACTH level), t2ULN (time to a decrease of the ACTH level <92 ng/L (= upper limit of normal multiplied with 2)), AUC0–360min and AUC0–240min (area under the concentration-time curve (ACTH) from zero to last sampling time). Cmin, t50 and t2ULN were obtained directly from the observed values. Cbaseline, ΔCbaseline-min and the AUC were calculated. AUC0–360min and AUC0–240min were assessed by the trapezoidal rule.
Statistical analysis

Statistical analysis was performed by PASW Statistics 24 (IBM SPSS, IBM Corp.). For comparison of the pharmacokinetics of VAG-PN to REC-PN (100 mg PN), as well as for the comparison of VAG-PN and REC-PN to s.c. and i.m. injection of 100 mg HC, a one-way ANOVA was used. Scheffé procedure and Dunnet-T3 test were used as post hoc tests. The assessment of bioequivalence (AUC$_{0-360}$ and C$_{max}$) was based upon the 90% confidence interval (CI) for the ratio of test (VAG-PN) and reference (REC-PN) administration (bioequivalence bounds: 80–125%). The CI was obtained from the ANOVA model on a log-transformed scale. This CI was back-transformed to obtain the CI for the ratio on the original scale. χ² test was used for comparison of the patients’ preference of administration mode. Data are presented as mean and CV (%) or median and range. The 95% CI, minimum (MIN) and maximum (MAX) values, as well as the P values were calculated. Differences were considered as statistically significant when P<0.05.

In a sub-analysis, plasma ACTH levels obtained in the current study were compared to data obtained from 12 patients with primary AI (five men, seven women) after i.m. and s.c. administration of 100 mg HC that had been investigated in another pharmacokinetic study (19). As six females had completed both studies, we additionally analyzed their data in another sub-analysis.

Results

Study cohort

Twelve female patients with primary AI caused by autoimmune adrenalitis were included. Six patients were premenopausal and six postmenopausal. Eleven patients completed all study visits, and one patient discontinued before completion and only received VAG-PN. Additional autoimmune thyroid disease was documented in 11 patients; one patient was diagnosed with premature ovarian failure. Median age was 51 years (range: 31–63) and median duration of primary AI was 12 years (2–33). BMI was 26 kg/m² (18–33). All patients were on stable steroid replacement therapy with HC (20 mg (10–30)) and fludrocortisone (0.05 mg (0.05–0.15)). Ten patients received levothyroxine replacement (81 μg (50–138)). No patient received any medication known to induce GC-metabolizing hepatic cytochrome P450 3A4 (26).

Pharmacokinetics of vaginal and rectal administration of prednisone

Prednisolone serum concentrations after VAG-PN compared to REC-PN are displayed in Fig. 2. After VAG-PN, no serum prednisolone levels could be detected at any time point during 360 min in five patients while after REC-PN, prednisolone levels were measurable in all patients. Pharmacokinetic parameters after PN administration are given in Table 1. Maximum serum prednisolone levels as well as the AUC$_{0-360}$ significantly differed after rectal...
and vaginal administration of 100 mg PN suppositories with lower values after VAG-PN (Table 1). The 90% CI for AUC$_{0-360}$ and C$_{\text{max}}$ (test/reference ratio) were not within the bioequivalence bounds (80–125%): AUC$_{0-360}$: 0.1–4.8% and C$_{\text{max}}$: 2.8–13%.

No significant correlation could be observed between BMI and the pharmacokinetic data (C$_{\text{max}}$, C$_{\text{av}}$, AUC$_{0-360}$ and MRT) after either administration. Furthermore, no significant correlation between the day of menstrual cycle and C$_{\text{max}}$, C$_{\text{av}}$, AUC$_{0-360}$ and the MRT was detected. The patient cohort was further divided into a pre- (n=6) and postmenopausal (n=6) group of women to investigate the potential influences on vaginal absorption of PN. Pharmacokinetic parameters did not differ between both groups. Moreover, no difference of pharmacokinetic parameters was observed in case of self-reported vaginal dryness. ACTH levels continuously decreased from 790 ng/L (54%) to 448 ng/L (68%) after VAG-PN and from 767 ng/L (47%) to 26 ng/L (67%) after REC-PN. The decrease in ACTH levels was significantly more pronounced after REC-PN compared to VAG-PN (Fig. 3). Minimal ACTH levels and the AUC$_{0-360}$ were significantly lower after REC-PN (Table 2). Pharmacokinetic parameters are provided in Table 2.

### Patient questionnaire

The questionnaire was completed by eleven patients (92%). In general, the patients rated their coping with the disease as ‘very good’ (n=1) or ‘good’ (n=9); one patient gave no answer. History of AC was reported by four patients (reported causes of AC: 66.7% gastroenteritis, 33.3%...

| Table 1 | Pharmacokinetic parameters after vaginal (n=12) and rectal (n=11) administration of prednisone (serum prednisolone concentrations). |
|---------|-----------------------------------------------------------------------------------------------------------------------------------|
| C$_{\text{max}}$ (ng/mL) | Vaginal | 22 (109) | 6.6–37 | 0 | 68 | <0.001 |
| Rectal | 161 (28) | 131–192 | 79 | 241 | |
| C$_{\text{av}}$ (ng/mL) | Vaginal | 11 (117) | 2.8–19 | 0 | 34 | <0.001 |
| Rectal | 102 (26) | 84–119 | 52 | 137 | |
| t$_{\text{max}}$ (min) | Vaginal | 309 (13) | 270–347 | 240 | 360 | 0.083 |
| Rectal | 251 (30) | 201–301 | 120 | 360 | |
| AUC$_{0-360}$ (ng/mL * min) | Vaginal | 4390 (116) | 1144–7636 | 0 | 13351 | <0.001 |
| Rectal | 40,302 (26) | 33,294–47,310 | 20,745 | 55,768 | |
| MRT (min) | Vaginal | 144 (89) | 62–226 | 0 | 298 | 0.101 |
| Rectal | 212 (10) | 198–226 | 179 | 251 | |
| t$_{\frac{1}{2}}$ (h) | Vaginal | 8 (96) | 0.9–15 | 1.6 | 22 | 0.137 |
| Rectal | 15 (69) | 8.2–22 | 2.9 | 33 | |

Analyses were performed by one-way ANOVA. Bold indicates statistical significance, P < 0.05.

AUC$_{0-360}$, area under the concentration-time curve from zero to last sampling time; C$_{\text{av}}$, average concentration; CI, confidence interval; C$_{\text{max}}$, maximum concentration; CV, coefficient of variation; MAX, maximum; MIN, minimum; MRT, mean residence time; t$_{\frac{1}{2}}$, half-life time; t$_{\text{max}}$, time to maximum concentration.
other febrile infections). All patients were equipped both with an emergency card and set (at least consisting of a 100 mg hydrocortisone ampoule for parenteral injection). Three patients already had self-injected HC in case of emergency; none of the patients had previously used a PN suppository. All study participants indicated that the opportunity to use PN suppositories as an alternative to HC self-injection would make them feel safer. Eight patients would use vaginal PN suppositories after study participation. Regarding the mode of GC administration in case of gastroenteritis (possible answers within this multiple-choice question were vaginal PN administration, s.c. or i.m. HC injection), one patient preferred i.m. injection of HC, three patients s.c. injection of HC and seven patients preferred vaginal administration of a PN suppository.

**Adverse events**

In total, 23 mild or moderate adverse events were documented in ten patients. After REC-PN, one patient reported increased fatigue and flushing and another patient reported dizziness. After VAG-PN, ten patients reported adverse events: four patients reported fatigue and two patients reported dizziness. Collapse, cephalgia, flushing, exertional dyspnea and nausea were reported by one patient, respectively. Local adverse events were reported by 50% of the patients: three patients developed Figure 3

Comparison of plasma adrenocorticotropic (ACTH) concentrations over time. Curves represent mean ACTH concentrations ± standard deviation. ACTH concentrations after rectal (n = 11) and vaginal (n = 12) administration of a 100 mg prednisone suppository (0–360 min) compared to subcutaneous (n = 12) and intramuscular (n = 12) injection of 100 mg hydrocortisone (0–240 min). The displayed data on subcutaneous and intramuscular injection of hydrocortisone was obtained from a separate study investigating a different patient cohort (19). Six patients of this previous trial were also participants in the current study.

| Table 2 | Effect of vaginal (n = 12) and rectal (n = 11) administration of 100 mg prednisone suppositories on ACTH values; kinetic parameters. |
| --- | --- | --- | --- | --- |
| **C**<sub>BASELINE</sub> (ng/L) | **Mean (CV %)** | **CI 95 %** | **MIN MAX** | **P** |
| **Vaginal** | 790 (54) | 520–1060 | 34 | 1254 | | |
| **Rectal** | 767 (47) | 527–1007 | 87 | 1250 | 0.891 |
| **C**<sub>MN</sub> (ng/L) | **Mean (CV %)** | **CI 95 %** | **MIN MAX** | **P** |
| **Vaginal** | 448 (68) | 255–641 | 21 | 844 | | |
| **Rectal** | 26 (67) | 14–138 | 12 | 75 | | |
| **ΔC**<sub>BASELINE–MIN</sub> (ng/L) | **Mean (CV %)** | **CI 95 %** | **MIN MAX** | **P** |
| **Vaginal** | 342 (63) | 204–479 | 13 | 747 | | |
| **Rectal** | 741 (48) | 502–980 | 72 | 1224 | | |
| **ΔC**<sub>BASELINE–MIN</sub> (%) | **Mean (CV %)** | **CI 95 %** | **MIN MAX** | **P** |
| **Vaginal** | 47 (44) | 34–60 | 11 | 86 | | |
| **Rectal** | 95 (5) | 92–98 | 83 | 99 | <0.001 |
| **AUC**<sub>0–360min</sub> (ng/L * min) | **Mean (CV %)** | **CI 95 %** | **MIN MAX** | **P** |
| **Vaginal** | 207457 (67) | 108,528–306,386 | 11,641 | 353,735 | 0.033 |
| **Rectal** | 95949 (43) | 68,152–123,746 | 16,512 | 168,042 | | |

Analyses were performed by one-way ANOVA. Bold indicates statistical significance, P < 0.05.

- **AUC**<sub>0–360min</sub> area under the concentration-time curve (ACTH) from zero to last sampling time; **C**<sub>BASELINE</sub>, baseline ACTH (mean of values −10 min and 0 min); **ΔC**<sub>BASELINE–MIN</sub>, difference between baseline and minimal ACTH levels after administration of prednisone; CI, confidence interval; **C**<sub>MN</sub>, minimal ACTH concentration after administration of prednisone; CV, coefficient of variation; MAX, maximum; MIN, minimum.
vaginal discharge, one patient developed a urinary tract infection as well as a vaginal mycosis and one patient reported local feeling of heat directly after administration. No severe adverse events occurred.

The symptoms after REC-PN lasted maximum 24 h and did not require any intervention. The general symptoms after VAG-PN were most likely caused by inadequate absorption of PN resulting in GC deficiency. Additional HC administration during the study procedures in one patient (values after HC administration were not included in analysis). General symptoms lasted 14 days in one patient; in all other patients 24–72 h. The urinary tract infection was treated by systemic antibiotic therapy and vaginal mycosis by local antifungal therapy.

**Comparison of PN suppositories versus subcutaneous and intramuscular injection of hydrocortisone**

Plasma ACTH levels were compared to data obtained in 12 patients with primary AI (five men, seven women) after i.m. and s.c. administration of 100 mg HC investigated in another pharmacokinetic study (19). Six participants of the current trial also had participated in the former study. The mean BMI of both study cohorts did not differ significantly (26 kg/m² vs 26 kg/m² in the current trial; \( p = 0.715 \)). The decline in mean ACTH levels, as a measure of the biological efficacy of the respective GCs, was slower both after REC-PN and VAG-PN (100 mg PN) compared to i.m. and s.c. injection of 100 mg HC (Fig. 3).

Pharmacokinetic parameters for ACTH levels after REC-PN compared to s.c. and i.m. injection of HC are shown in Table 3. ACTH levels were significantly lower after s.c. (17 ng/L (51%); \( p = 0.022 \)) and i.m. (14 ng/L (64%); \( p = 0.018 \)) injection of HC compared to REC-PN (79 ng/L (78%)). The time to a 50% decrease of baseline ACTH values was significantly longer after REC-PN compared to s.c. (\( p < 0.001 \)) and i.m. (\( p < 0.001 \)) injection of HC, while there was no significant difference between s.c. and i.m. administration of HC (\( p = 0.971 \)). After VAG-PN, the maximum decline of ACTH levels compared to baseline values was 44% after 360 min. A similar pattern of decline of ACTH levels was found for all investigated routes of administration when only ACTH levels of the six female patients that participated in both studies were compared (Supplementary Fig. 1, see section on supplementary data given at the end of this article). Again, the time to a 50% decrease of baseline ACTH values was significantly longer after REC-PN compared to s.c. and i.m. injection of HC.

**Discussion**

Our study documents the pharmacokinetic profile of a commercially available PN suppository after both vaginal and rectal administration in female patients with AI. After REC-PN, drug levels were seen in every patient and the pharmacokinetic results are comparable to available data from healthy subjects (27). In contrast, insufficient bioavailability is observed after VAG-PN, clearly demonstrating that this administration route should be avoided at least when using the currently available galenic formulation. Maximum serum prednisolone concentrations and the AUC\(_{0–360}\) were significantly lower after VAG-PN compared to REC-PN. Five patients did not achieve any measurable prednisolone levels during 360 min. In addition, there were more adverse events after VAG-PN, which were most likely due to the insufficient absorption and the resulting GC deficiency as the patients had to postpone their morning GC dose. Local adverse events were also more frequent after VAG-PN.

The used PN suppository was established for rectal use. Therefore, the vaginal pH value and anatomy might have impaired the vaginal absorption of the suppository. The composition of the PN suppository with a high ratio of hydrogenated fat may have contributed to the reduced vaginal absorption. Furthermore, sphincter tone better prevents an uncontrolled passing after rectal use. After VAG-PN three patients described vaginal discharge during the study visit. Since relevant drug levels are achieved after vaginal administration of other medications (e.g. misoprostol) (28, 29), it cannot be generally assumed that this mode of administration is associated with an impaired absorption. In an emergency situation, however, rapid GC availability must be ensured.

It remains to be defined which time intervals and GC levels may be considered as safe. In a previous study, we postulated that the time needed to reach cortisol levels of >36 µg/dL (>1000 nmol/L) does not exceed 30 min (19). This value is twice the cutoff level required to pass the short Synacthen test, representing a maximum ACTH stimulus. The cut-off was achieved both after i.m. and s.c. HC (19). Median prednisolone levels 45 min after rectal administration in our current study were 4.9 µg/dL (2–9.6) (136 nmol/L (56–266)). The relative GC potency between prednisolone and HC has been calculated as 1:4–8 (30, 31). The suppressive effect on ACTH secretion was delayed and less pronounced after administration of PN suppositories compared to s.c. and i.m. administration of 100 mg HC (19) and the minimal ACTH levels (\( C_{\text{MIN}} \)) achieved after REC-PN remained significantly higher compared to those...
Table 3  Effect on ACTH values after rectal (n = 11) administration of 100 mg prednisone versus subcutaneous (n = 12) and intramuscular (n = 12) administration of 100 mg hydrocortisone; kinetic parameters.

| Parameter            | Mean (CV %) | CI 95 %       | MIN MAX | P     |
|----------------------|-------------|---------------|---------|-------|
| **C_BASELINE (ng/L)**|             |               |         |       |
| Rectal               | 767 (47)    | 527–1007      | 87      | 1250  |
| s.c.                 | 946 (65)    | 553–1339      | 66      | 2068  |
| i.m.                 | 724 (67)    | 415–1033      | 113     | 1991  |
| **C_MIN (ng/L)**     |             |               |         |       |
| Rectal               | 79 (78)     | 37–121        | 28      | 213   |
| s.c.                 | 17 (61)     | 37–121        | 0       | 28    |
| i.m.                 | 14 (64)     | 8.4–20        | 0       | 27    |

Dunnett-T3: (1) rectal versus s.c.: \( P = 0.022 \); (2) rectal versus i.m.: \( P = 0.018 \); (3) s.c. versus i.m. 0.883

\[ \Delta C_{\text{BASELINE-MIN}}(\%) \]

| Parameter            | Mean (CV %) | CI 95 %       | MIN MAX | P     |
|----------------------|-------------|---------------|---------|-------|
| **t_{50} (min)**     |             |               |         |       |
| Rectal               | 86 (15)     | 77–95         | 57      | 97    |
| s.c.                 | 98 (1)      | 98–99         | 97      | 100   |
| i.m.                 | 98 (1)      | 97–99         | 96      | 100   |

Dunnett-T3: (1) rectal versus s.c.: \( P = 0.030 \); (2) rectal versus i.m.: \( P = 0.031 \); (3) s.c. versus i.m. 0.995

\[ \Delta C_{\text{BASELINE-MIN}}(\%) \]

| Parameter            | Mean (CV %) | CI 95 %       | MIN MAX | P     |
|----------------------|-------------|---------------|---------|-------|
| **t_{2ULN} (min)**   |             |               |         |       |
| Rectal               | 149 (31)    | 117–180       | 75      | 240   |
| s.c.                 | 60 (26)     | 50–70         | 45      | 75    |
| i.m.                 | 58 (27)     | 48–67         | 45      | 75    |

Dunnett-T3: (1) rectal versus s.c.: \( P < 0.001 \); (2) rectal versus i.m.: \( P < 0.001 \); (3) s.c. versus i.m. 0.971

\[ \Delta C_{\text{BASELINE-MIN}}(\%) \]

| Parameter            | Mean (CV %) | CI 95 %       | MIN MAX | P     |
|----------------------|-------------|---------------|---------|-------|
| **AUC_{0-240min} (ng/L * min)** |            |               |         |       |
| Rectal               | 90,419 (43) | 64,146–116,693 | 13,899 | 156,720 |
| s.c.                 | 56,078 (62) | 33,895–78,261  | 3826   | 122,719 |
| i.m.                 | 40,993 (62) | 24,864–57,121  | 10,040 | 104,757 |

Schefé: (1) rectal versus s.c.: \( P = 0.063 \); (2) rectal versus i.m.: \( P = 0.005 \); (3) s.c. versus i.m. 0.549

Analyses were performed by one-way ANOVA. Post hoc tests: Scheffé procedure and Dunnet-T3. Bold indicates statistical significance, \( P < 0.05 \).

The superiority of parenteral GC administration, however, only holds true if treatment is initiated within similar time intervals. Delays may result from the time-consuming preparation of injections and fear to self-inject (17). A patient-friendly ready-to-use HC syringe is unavailable (15, 17). Most of the patients in our study (64%) preferred the use of suppositories over GC injection in case of emergency provided that safety is similarly guaranteed. However, the patients’ preference was only assessed within a small number of female patients and might vary in a larger and more heterogeneous cohort. It has furthermore not been investigated if suppositories are administered in a shorter period of time in case of incipient AC. Nevertheless, all study participants stated that the option of using suppositories would make them feel safer and increase their general well-being.

As PN is converted to prednisolone by hepatic 11beta-hydroxysteroid dehydrogenase type 1 (25), it may be assumed that use of prednisolone or HC suppositories result in faster GC effects (32). Our study only investigated the standard dose of 100 mg PN. It might be speculated that higher PN doses improve the pharmacokinetic outcome.

In conclusion, vaginal administration of PN suppositories in the investigated available galenic composition is not sufficient for prevention or treatment of AC. Although sufficient drug levels were observed over...
time after REC-PN, it cannot be regarded as equivalent to parenteral administration of GC for treatment of adrenal emergencies. On the background of the available data, GC injection should be recommended to the patients as the first choice to prevent or treat AC until adequate professional medical care is available.

**Supplementary data**
This is linked to the online version of the paper at https://doi.org/10.1530/EC-19-0024.

**Declaration of interest**
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**
This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-No. 314061271 – TRR 205 as well as a research grant to S Burger-Stritt from the IZKF Wuerzburg (Project-No.: Z-2/62).

**Author contribution statement**
S Burger-Stritt was involved in the design of study, preparation of study protocol and applications for authorities, conduct of the study, data analysis and preparation of the manuscript. L Bachmann was involved in the preparation of applications for authorities, conduct of the study, laboratory measurements and data analysis. M Kurbbaum was involved in pharmacokinetic analysis and preparation of the manuscript. S Hahner was involved in design of study, preparation of study protocol and applications for authorities, data analysis and preparation of the manuscript.

**Acknowledgements**
The authors thank the team of the Endocrine Outpatient Clinic, Department of Internal Medicine I, University Hospital Wuerzburg, especially the team of the endocrine laboratory, for their excellent cooperation.

**References**

1. Berghorsdottir R, Leonsson-Zachtsson M, Oden A & Johansson G. Premature mortality in patients with Addison’s disease: a population-based study. *Journal of Clinical Endocrinology and Metabolism* 2006 91 4849–4853. (https://doi.org/10.1210/jc.2006-0076)

2. Bensing S, Brandt L, Tabaraj F, Sjöberg O, Nilsson B, Ekholm A, Blomqvist P & Kampe O. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. *Clinical Endocrinology* 2008 69 697–704. (https://doi.org/10.1111/j.1365-2265.2008.0340.x)

3. Erichsen MM, Lovas K, Fougner KJ, Svarthjelm J, Hauge ER, Bøllerslev J, Berg JP, Mella B & Husebye ES. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. *European Journal of Endocrinology* 2009 160 233–237. (https://doi.org/10.1530/EJE-08-0550)

4. Burman P, Mattsson AE, Johansson G, Hoyer B, Holmer H, Dahlqvist P, Berinder K, Engstrom BE, Ekmann B, Erfurth EM, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. *Journal of Clinical Endocrinology and Metabolism* 2013 98 1466–1475. (https://doi.org/10.1210/jc.2012-4059)

5. Hahner S, Loefler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M, Venz M, Quinkler M & Allolio B. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. *European Journal of Endocrinology* 2010 162 597–602. (https://doi.org/10.1530/EJE-09-0884)

6. Rushworth RL & Torpy DJ. A descriptive study of adrenal crises in adults with adrenal insufficiency: increased risk with age and in those with bacterial infections. *BMC Endocrine Disorders* 2014 14 79. (https://doi.org/10.1186/1472-6823-14-79)

7. Smans LCCJ, Van der Valk IS, Hermus ARM & Zelissen PMJ. Incidence of adrenal crisis in patients with adrenal insufficiency. *Clinical Endocrinology* 2016 84 17–22. (https://doi.org/10.1111/cen.12865)

8. Meyer G, Badenhoop K & Linder R. Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010–2013. *Clinical Endocrinology* 2016 85 347–353. (https://doi.org/10.1111/cen.13043)

9. Fahhammar H, Friesen L, Norby C, Hirschberg AL, Almqvist C, Nordenskjold A & Nordenstrom A. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Journal of Clinical Endocrinology and Metabolism* 2014 99 E2715–E2721. (https://doi.org/10.1210/jc.2014-2957)

10. Reisch N, Willige M, Kohn D, Schwarz HP, Allolio B, Reinecke M, Quinkler M, Hahner S & Beuschlein F. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. *European Journal of Endocrinology* 2012 167 35–42. (https://doi.org/10.1530/EJE-12-0161)

11. Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K, Milovanovic D, Beuschlein F, Wilkenberg HS, Quinkler M & Allolio B. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. *Journal of Clinical Endocrinology and Metabolism* 2015 100 407–416. (https://doi.org/10.1210/jc.2014-3191)

12. Repping-Wuts HJ, Stikkelbroeck NM, Noordzij A, Kerstens M & Hermus AR. A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. *European Journal of Endocrinology* 2013 169 17–22. (https://doi.org/10.1530/EJE-12-1094)

13. Allolio B. EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: Adrenal crisis. *European Journal of Endocrinology* 2015 172 R115–R124. (https://doi.org/10.1530/EJE-14-0824)

14. Bornstein SR, Allolio B, Ahr W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism* 2016 101 364–389. (https://doi.org/10.1210/jc.2015-1710)

15. Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C & Allolio B. Timelines in the management of adrenal crisis – targets, limits and reality. *Clinical Endocrinology* 2015 82 497–502. (https://doi.org/10.1111/cen.12609)

16. Kampmeyer D, Lehnert H, Moenig H, Haas CS & Harbeck B. A strong need for improving the education of physicians on glucocorticoid replacement treatment in adrenal insufficiency: an interdisciplinary and multicentre evaluation. *European Journal of Internal Medicine* 2016 33 e13–e15. (https://doi.org/10.1016/j.ejim.2016.04.006)

17. Burger-Stritt S, Kardonski P, Pulzer A, Meyer G, Quinkler M & Hahner S. Management of adrenal emergencies in educated patients with adrenal insufficiency – a prospective study. *Clinical Endocrinology* 2018 89 22–29. (https://doi.org/10.1111/cen.13608)

18. Eff A, Burger-Stritt S, Quinkler M, Horn S, Rüger W, Pulzer A, Pahl S, Norkeweit J, Bauer B, Kienitz T, et al. Evaluation of a German-wide education programme for patients with adrenal insufficiency – first interim analysis. *DACH-Tagung 2016 Abstracts*, abstract POI-13.
Munich, Germany: Deutsche Gesellschaft für Endokrinologie, 2016. Abstract P01-13. (available at: https://docplayer.net/46935771-59-symposium-der-deutschen-gesellschaft-fur-endokrinologie.html)

19 Hahner S, Burger-Stritt S & Alloizio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. *European Journal of Endocrinology* 2013 169 147–154. (https://doi.org/10.1530/EJE-12-1057)

20 Simunkova K & Husebye ES. Adrenal insufficiency therapy: how to keep the balance between good quality of life and low risk for long-term side effects? *Frontiers of Hormone Research* 2016 46 196–210. (https://doi.org/10.1159/000443920)

21 Bensing S, Hulting AL, Husebye ES, Kampe O & Lovas K. MANAGEMENT OF ENDOCRINE DISEASE: Epidemiology, quality of life and complications of primary adrenal insufficiency: a review. *European Journal of Endocrinology* 2016 175 R107–R116. (https://doi.org/10.1530/EJE-15-1242)

22 Puar THK, Stikkelbroeck NMML, Smans LCCJ, Zelissen PMJ & Hermus ARMM. Adrenal crisis: still a deadly event in the 21st century. *American Journal of Medicine* 2016 129 339.e1–339.e9. (https://doi.org/10.1016/j.amjmed.2015.08.021)

23 Grossman A, Johannsson G, Quinkler M & Zelissen P. THERAPY OF ENDOCRINE DISEASE: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. *European Journal of Endocrinology* 2013 169 R165–R175. (https://doi.org/10.1530/EJE-13-0450)

24 Johansson G, Falorni A, Skrötter S, Lennernas H, Quinkler M, Monson JP & Stewart PM. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. *Clinical Endocrinology* 2015 82 2–11. (https://doi.org/10.1111/cen.12603)

25 Jenkins JS & Sampson PA. Conversion of cortisone to cortisol and prednisone to prednisolone. *BMJ* 1967 2 205–207. (https://doi.org/10.1136/bmj.2.5546.205)

26 Dresser GK, Spence JD & Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clinical Pharmacokinetics* 2000 38 41–57. (https://doi.org/10.2165/00003088-200038010-00003)

27 Beubler E & Dittrich P. About the therapy of laryngotracheitis (croup): significance of rectal dosage forms. *Pharmacology* 2015 95 300–302. (https://doi.org/10.1159/000430890)

28 Khan RU, El-Refaey H, Sharma S, Sooranna D & Stafford M. Oral, rectal, and vaginal pharmacokinetics of misoprostol. *Obstetrics and Gynecology* 2004 103 866–870. (https://doi.org/10.1097/01.AOG.0000124783.38974.53)

29 Tang OS, Gemzell-Danielsson K & Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. *International Journal of Gynecology and Obstetrics* 2007 99 (Supplement 2) S160–S167. (https://doi.org/10.1016/j.ijigo.2007.09.004)

30 Cardato MCE, Fernandes VT & Kater CE. One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency. *Arquivos Brasileiros de Endocrinologia and Metabolism* 2004 48 705–712. (https://doi.org/10.1590/S0004-27302004000500017)

31 Khalid BAK, Burke CW, Hurley DM, Funder JW & Stockigt JR. Steroid replacement in Addison's disease and in subjects adrenalectomized for Cushing's disease: comparison of various glucocorticoids. *Journal of Clinical Endocrinology and Metabolism* 1982 55 551–559. (https://doi.org/10.1210/jcem-55-3-551)

32 Mehlaus-Barlet N, Kummer M & Kunz K. Absolute bioverfügbarkeit von prednisolon nach applikation einer rektalkapsel. *Therapiewoche* 1988 38 209–2012.

Received in final form 8 March 2019
Accepted 18 March 2019